James Hu

2.7k total citations
51 papers, 626 citations indexed

About

James Hu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, James Hu has authored 51 papers receiving a total of 626 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Pulmonary and Respiratory Medicine, 26 papers in Oncology and 15 papers in Surgery. Recurrent topics in James Hu's work include Sarcoma Diagnosis and Treatment (23 papers), Vascular Tumors and Angiosarcomas (9 papers) and Testicular diseases and treatments (8 papers). James Hu is often cited by papers focused on Sarcoma Diagnosis and Treatment (23 papers), Vascular Tumors and Angiosarcomas (9 papers) and Testicular diseases and treatments (8 papers). James Hu collaborates with scholars based in United States, Canada and United Kingdom. James Hu's co-authors include William W. Tseng, Gino K. In, Melissa Burgess, Richard F. Riedel, Brian Andrew Van Tine, Sandra P. D’Angelo, Lara E. Davis, Denise K. Reinke, Robert G. Maki and Shreyaskumar Patel and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

James Hu

49 papers receiving 621 citations

Peers

James Hu
Eve T. Rodler United States
Daniela Katz Israel
Tianshu Liu China
Brent Shoji United States
Kwai Han Yoo South Korea
Seyoung Seo South Korea
Andréa Moretti Italy
Rümeysa Çiftçi Türkiye
Cheuk Hong Leung United States
Eve T. Rodler United States
James Hu
Citations per year, relative to James Hu James Hu (= 1×) peers Eve T. Rodler

Countries citing papers authored by James Hu

Since Specialization
Citations

This map shows the geographic impact of James Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Hu more than expected).

Fields of papers citing papers by James Hu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Hu. The network helps show where James Hu may publish in the future.

Co-authorship network of co-authors of James Hu

This figure shows the co-authorship network connecting the top 25 collaborators of James Hu. A scholar is included among the top collaborators of James Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Hu. James Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hu, James, et al.. (2024). Physician Leadership and Burnout: The Need for Agency; a Qualitative Study of an Academic Institution. Journal of Healthcare Leadership. Volume 16. 121–130. 3 indexed citations
2.
Ito, Fumito, Shelly X. Bian, Andrew Lim, et al.. (2024). A phase 1 trial in progress for in situ immunomodulation with CDX-301, radiation therapy, poly-ICLC, and CDX-1140 in patients with unresectable and metastatic solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS2697–TPS2697. 2 indexed citations
3.
Meyer, Christian F., Matthew Ingham, James Hu, et al.. (2023). Intratumoral INT230-6 (cisplatin, vinblastine, shao) alone or with ipilimumab prolonged survival with favorable safety in adults with refractory sarcomas.. Journal of Clinical Oncology. 41(16_suppl). 11568–11568. 3 indexed citations
4.
Patel, Dakshesh B., et al.. (2022). Remission of a Primary, Recurrent Thoracic Ewing Sarcoma in a 74-year-old woman. SHILAP Revista de lepidopterología. 14. 2 indexed citations
5.
Chen, Xiao T., et al.. (2022). Tumor lysis syndrome following ifosfamide monotherapy in metastatic osteosarcoma: a case report and review of the literature. Journal of Medical Case Reports. 16(1). 252–252. 2 indexed citations
6.
Patterson, Pandora, Norma Mammone D’Agostino, Fiona E. J. McDonald, et al.. (2021). Screening for distress and needs: Findings from a multinational validation of the Adolescent and Young Adult Psycho‐Oncology Screening Tool with newly diagnosed patients. Psycho-Oncology. 30(11). 1849–1858. 30 indexed citations
7.
Ingham, Matthew, James Hu, Giles F. Whalen, et al.. (2021). Early results of intratumoral INT230-6 alone or in combination with ipilimumab in subjects with advanced sarcomas.. Journal of Clinical Oncology. 39(15_suppl). 11557–11557. 3 indexed citations
8.
Choi, April, Philip M. Carpenter, Shefali Chopra, et al.. (2020). Spindle cell carcinoma of the breast managed with neoadjuvant AIM: A case report. Rare Tumors. 12. 1361826429–1361826429. 2 indexed citations
9.
Martín‐Broto, Javier, Antonio López–Pousa, Andrew S. Brohl, et al.. (2020). Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. Molecular Cancer Therapeutics. 20(1). 132–141. 9 indexed citations
10.
Tseng, William W., Jun Chen, Dakshesh B. Patel, et al.. (2020). Multidisciplinary sarcoma tumor board: retroperitoneal liposarcoma. Chinese Clinical Oncology. 9(2). 20–20. 8 indexed citations
11.
Jayachandran, Priya, Dakshesh B. Patel, James Hu, et al.. (2020). Multidisciplinary sarcoma tumor board: adolescent and young adult soft tissue sarcoma—myxoid liposarcoma and alveolar soft part sarcoma. Chinese Clinical Oncology. 9(5). 67–67. 5 indexed citations
12.
Fields, Brandon K.K., Darryl Hwang, Steven Cen, et al.. (2020). Quantitative magnetic resonance imaging (q-MRI) for the assessment of soft-tissue sarcoma treatment response: a narrative case review of technique development. Clinical Imaging. 63. 83–93. 19 indexed citations
13.
Lin, Michelle, Li Ding, James Hu, et al.. (2020). Predictors of readmission after craniotomy for meningioma resection: a nationwide readmission database analysis. Acta Neurochirurgica. 162(11). 2637–2646. 8 indexed citations
14.
15.
Dorff, Tanya B., Jeff Longmate, Sumanta K. Pal, et al.. (2017). Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer. 123(23). 4566–4573. 36 indexed citations
16.
Burgess, Melissa, Vanessa Bolejack, Brian Andrew Van Tine, et al.. (2017). Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses.. Journal of Clinical Oncology. 35(15_suppl). 11008–11008. 31 indexed citations
17.
Burgess, Melissa, Jason Roszik, Brian Andrew Van Tine, et al.. (2017). Correlation of circulating PD-L2 levels with outcomes of therapy with the anti-PD-1 antibody pembrolizumab (P) in patients (pts) with advanced soft tissue sarcomas (STS): Biomarker analysis of SARC028.. Journal of Clinical Oncology. 35(7_suppl). 60–60. 3 indexed citations
18.
Hu, James, George R. Matcuk, Shefali Chopra, et al.. (2015). Contemporary Management of Retroperitoneal Soft Tissue Sarcomas. Current Oncology Reports. 17(8). 39–39. 21 indexed citations
19.
Feldman, Darren R., James Hu, Tanya B. Dorff, et al.. (2013). Paclitaxel, ifosfamide, and cisplatin (TIP) efficacy for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).. Journal of Clinical Oncology. 31(15_suppl). 4501–4501. 3 indexed citations
20.
Hendifar, Andrew, Elke R. Ahlmann, Daniel C. Allison, et al.. (2012). Moving Beyond Response Criteria: New Measures of Success in the Treatment of Sarcomas. Current Treatment Options in Oncology. 13(3). 299–305. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eve T. Rodler Breakdown of academic impact, for papers by Daniela Katz Breakdown of academic impact, for papers by Tianshu Liu Breakdown of academic impact, for papers by Brent Shoji Breakdown of academic impact, for papers by Kwai Han Yoo Breakdown of academic impact, for papers by Seyoung Seo Breakdown of academic impact, for papers by Andréa Moretti Breakdown of academic impact, for papers by Rümeysa Çiftçi Breakdown of academic impact, for papers by Cheuk Hong Leung
Rankless by CCL
2026